24 studies found for:    EpCAM
Show Display Options
Rank Status Study
1 Completed Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
Conditions: EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast);   Malignant Ascites
Interventions: Biological: Catumaxomab (Removab);   Procedure: paracentesis
2 Completed Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
Conditions: Ovarian Cancer;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Intervention: Biological: anti-EpCAM x anti-CD3 (removab)
3 Completed EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
Conditions: Ovarian Cancer;   Colorectal Cancer;   Carcinoma, Non-small-cell Lung;   Prostate Cancer
Intervention: Drug: EMD 273066
4 Recruiting Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
Conditions: Prostate Cancer;   Renal Cell Carcinoma;   Bladder Cancer;   Colorectal Cancer;   Gastric Cancer;   Pancreatic Cancer
Interventions: Device: Mesenchymal-marker based ferrofluid (c-MET);   Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid
5 Recruiting Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases
Condition: Meningeal Carcinomatosis
Intervention: Procedure: lumbar puncture
6 Completed Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma
Conditions: Gastric Cancer;   Gastric Adenocarcinoma
Intervention: Drug: catumaxomab
7 Withdrawn Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
Condition: Metastatic Solid Tumors
Intervention: Drug: Cell therapy with bispecific antibodies
8 Recruiting Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas
Conditions: Gastric Adenocarcinoma With Peritoneal Carcinomatosis;   Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis;   Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
Interventions: Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel;   Drug: Fluorouracil, leucovorin, oxaliplatin, docetaxel
9 Terminated Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin
Condition: Neoplasms, Glandular and Epithelial
Intervention: Drug: VB6-845
10 Completed Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer
Intervention: Drug: Catumaxomab
11 Completed
Has Results
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Condition: Ovarian Cancer
Intervention: Drug: catumaxomab
12 Completed Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection
Conditions: Gastric Cancer;   Gastric Adenocarcinoma
Interventions: Drug: Catumaxomab;   Drug: catumaxomab
13 Completed
Has Results
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Condition: Malignant Ascites
Intervention: Drug: catumaxomab
14 Active, not recruiting Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Condition: Solid Tumors
Intervention: Biological: MT110
15 Recruiting Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology
Condition: Non Small Cell Lung Cancer
Intervention:
16 Completed CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
Conditions: Cancer;   Neoplasms;   Carcinoma;   Malignant Ascites
Interventions: Drug: Catumaxomab;   Drug: Prednisolone
17 Withdrawn Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507
Condition: Lung Cancer
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis
18 Recruiting Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology
Condition: Prostate Cancer
Intervention: Device: Near infrared (NIR) emissive nanotechnology
19 Unknown  China CellSearch Study
Conditions: Metastatic Breast Cancer;   Benign Breast Disease
Intervention:
20 Terminated Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer
Conditions: Peritoneal Carcinomatosis;   Gastrointestinal Cancer
Intervention: Procedure: Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)

Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results
Indicates status has not been verified in more than two years